As AI increasingly aids medical discoveries, questions arise about recognition and credit for breakthroughs, potentially reshaping the scientific landscape.
On Monday, the Nobel Prize for medicine was announced, sparking fascinating discussions about the role of artificial intelligence (AI) in medical achievements. Will AI like Claude or its successors ever find themselves in contention for such coveted accolades?
Imagine an advanced AI agent suggesting a groundbreaking cancer treatment based on a scientist's thought-provoking query, presenting a concrete plan for its execution. Few would argue against the merit of such an outcome given the persistent challenge of cancer. However, a deeper question lingers: How would we assign credit for this significant breakthrough?
In my tenure as a medical school dean, I often navigated the nuanced terrain of credit assignment in scientific research. Traditionally, credit has been bestowed upon human scientists whose discoveries have not only shaped medical science but have often earned them prestigious awards, including the Nobel Prize. But as we stand on the brink of AI's potential to drive significant scientific advancements, we must contemplate whether future prizes will honor AI entities like Claude instead of human pioneers. If such a shift occurs, what implications would it have?
The Nobel statutes refer to “persons” without specifying that these must be human, raising the possibility that credit could be redirected in a future where AI plays a pivotal role in discovery. For instance, the 2024 Nobel Prize in chemistry recognized winners who worked on the AlphaFold project at DeepMind, reflecting how collaborative efforts can complicate the concept of credit. As we think about AI making significant discoveries, it’s conceivable that recognition will initially go to the people who developed these systems rather than the AI itself.
Today, credit serves as the foundation of the scientific reward system, shaping research practices and influencing funding, job opportunities, and promotional pathways. It is considered the currency that validates scientists’ work and ensures accountability in claims and findings. The existing credit ecosystem, which emerged in the mid-19th century alongside professional science, has transformed through technological, societal, and collaborative developments over the years.
As AI settles into an essential role in scientific discovery, will our approach to credit evolve similarly? Current and emerging scientists are eager for clarity on how their efforts and those of AI will be valued. Despite the uncertainties, one probable scenario is a continuity of human involvement in discovery, supported by AI assistance. In this model, humans would still garner credit for their work while acknowledging AI’s contributions.
Conversely, if we recognize AI as an independent agent generating impactful discoveries—like a potential cancer cure—it raises further challenges about credit assignment. Would the traditional concept of credit still hold value?
In a scenario where AI-driven discoveries dominate, humans might still wish to recognize AI's role, potentially extending traditional accolades to AI systems. Furthermore, credit could also include human contributors who formulated the original queries, as well as those who implemented the AI’s findings in real-world applications.
Yet, the trajectory of credit's role in scientific discovery would inherently shift in a landscape where AI plays a primary role. Beyond academia, credit also influences commerce, especially concerning biomedical research where patents signify ownership of discoveries. Currently, patent laws only accommodate human inventors as named discoverers. If regulations evolve to allow for AI recognition as inventors, this could significantly alter the landscape of accountability and profit-sharing from scientific advancements.
Currently, in both academic settings and commercial enterprises, intellectual property rights tend to reside with the organizations rather than the individual inventors listed in patent filings. Changes in patent legislation to include AI agents could reshape ownership dynamics and accountability measures, particularly in cases where humans continue to play a creative role in realizing AI-generated concepts.
The scientific community thrives on competition and recognition, which has fueled many breakthroughs in research. As AI becomes more central to discovery processes, the cultural underpinnings of credit in science will need to adapt. Shifts in the credit economy may be necessary trade-offs as we harness AI's potential to enhance research outcomes across various fields.
Ultimately, whether AI agents like Claude will be celebrated with a Nobel Prize hinges on what we desire from the notion of credit. If the primary function of credit is to motivate human scientists, as AI's role grows, the current credit system may become increasingly obsolete. However, if accountability and trust continue to ride on credit assignment, these responsibilities will remain important, necessitating careful thought on how to navigate this evolving landscape, especially as discussions about AI evolving into moral agents gain momentum.
In contemplating these changes, one wonders how the credit structure will transform amid advances in AI. Institutions devoted to fostering research, from universities and funding bodies to biopharmaceutical companies, will each face decisions about the nature and assignment of credit in a domain leaning heavily on AI contributions. While the legacy of human discoverers may not fade entirely, amplifying conversations around AI's integration in science is essential as we step into this new frontier of research.
Jeffrey S. Flier is a Harvard University distinguished service professor and the former dean of Harvard Medical School.
Discussion
Sign in to join the discussion.